Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172097 | 1.00 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MAPK1NPSR1HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL28246804 | 0.98 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2MAPK1NPSR1HSD17B10 | |
| Benzene SCHEMBL27598766 | 0.96 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2MAPK1NPSR1HSD17B10 | |
| (Z)-1,2-Diphenylethene SCHEMBL27512705 | 0.85 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2MAPK1NPSR1HSD17B10 | |
| SCHEMBL6650934 | 0.84 | FFAR1 (0.48) | ALDH1A1SMN1; SMN2MAPK1NPSR1HSD17B10 | |
| SCHEMBL29870814 | 0.83 | RAB9A (0.54) | ALDH1A1SMN1; SMN2MAPK1NPSR1HSD17B10 | |
| SCHEMBL266440 | 0.83 | RAB9A (0.54) | ALDH1A1SMN1; SMN2MAPK1NPSR1HSD17B10 | |
| SCHEMBL9143839 | 0.81 | RAB9A (0.44) | ALDH1A1SMN1; SMN2MAPK1NPSR1HSD17B10 | |
| SCHEMBL16478922 | 0.80 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2MAPK1NPSR1HSD17B10 | |
| SCHEMBL27531501 | 0.79 | CYP1A2 (0.46) | ALDH1A1SMN1; SMN2MAPK1NPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | CHECKMATE THERAPEUTICS INC. (KR) | 2026-01-22 | — | — | US | disclosed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| EP-4385641-A1 | PROTECTED METAL ALLOY POWDER | COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (FR) | 2024-06-19 | — | — | EP | disclosed |
| US-11891387-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-06 | — | — | US | disclosed |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2023-10-12 | — | — | US | disclosed |
| US-20220372030-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-24 | — | — | US | disclosed |
| CN-115175909-A | Pyrrolopyridine and imidazopyridine antiviral compounds | 鲁汶天主教大学 | 2022-10-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | ALDH1A1 252/4885SMN1; SMN2 1579/4885MAPK1 4226/4885 |
| US-11891387-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | ALDH1A1 252/4885SMN1; SMN2 1579/4885MAPK1 4226/4885 |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | ALDH1A1 2551/4885SMN1; SMN2 755/4885MAPK1 4088/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | ALDH1A1 800/4885SMN1; SMN2 1208/4885MAPK1 419/4885 |
| US-20220372030-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | ALDH1A1 252/4885SMN1; SMN2 1579/4885MAPK1 4226/4885 |
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | NAMPT, NAPRT, NNT | ALDH1A1 789/4885SMN1; SMN2 2571/4885MAPK1 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.